TrialLancet (London, England)2023

Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.

Joe Y Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.